Cysteine Depletion Causes Oxidative Stress and Triggers Outer Membrane Vesicle Release by Neisseria meningitidis; Implications for Vaccine Development

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  van de Waterbeemd, Bas ^a   Zomer, Gijsbert ^a   van den IJssel, Jan ^a   van Keulen, Lonneke ^a   Eppink, Michel H ^b   van der Ley, Peter ^a   van der Pol, Leo A ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b WAGENINGEN UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL VACCINE; CYSTEINE; IRON SULFUR PROTEIN; NEISSERIA MENINGITIDIS VACCINE; REACTIVE OXYGEN METABOLITE; TRANSCRIPTOME; UNCLASSIFIED DRUG;

ARTICLE; BACTERIAL GROWTH; BACTERIAL VIRULENCE; CONTROLLED STUDY; GENE EXPRESSION; INTRACELLULAR SIGNALING; MEMBRANE VESICLE; NEISSERIA MENINGITIDIS; NONHUMAN; OXIDATIVE STRESS; PROTEIN ASSEMBLY; VACCINE PRODUCTION;

BACTERIAL OUTER MEMBRANE PROTEINS; BIOREACTORS; CELL MEMBRANE; CULTURE MEDIA; CYSTEINE; HUMANS; IRON-SULFUR PROTEINS; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS, SEROGROUP B; OXIDATIVE STRESS; PROTEOME;

BACTERIA (MICROORGANISMS); NEISSERIA MENINGITIDIS; NEISSERIA MENINGITIDIS SEROGROUP B; OAT MOSAIC VIRUS;

EID: 84872823871     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0054314     Document Type: Article

References (63)

1. Ellis TN, Kuehn MJ, (2010) Virulence and immunomodulatory roles of bacterial outer membrane vesicles. Microbiol Mol Biol Rev 74: 81-94.
2. Deatherage BL, Lara JC, Bergsbaken T, Rassoulian Barrett SL, Lara S, et al. (2009) Biogenesis of bacterial membrane vesicles. Mol Microbiol 72: 1395-1407.
3. Unal CM, Schaar V, Riesbeck K, (2011) Bacterial outer membrane vesicles in disease and preventive medicine. Semin Immunopathol 33: 395-408.
4. Namork E, Brandtzaeg P, (2002) Fatal meningococcal septicaemia with "blebbing" meningococcus. Lancet 360: 1741.
5. Kulp A, Kuehn MJ, (2010) Biological functions and biogenesis of secreted bacterial Outer Membrane Vesicles. Annual Review of Microbiology 64: 163-184.
6. Sierra GV, Campa HC, Varcacel NM, Garcia IL, Izquierdo PL, et al. (1991) Vaccine against group B Neisseria meningitidis: protection trial and mass vaccination results in Cuba. NIPH Ann 14: 195-207; discussion 208-110.
7. Bjune G, Hoiby EA, Gronnesby JK, Arnesen O, Fredriksen JH, et al. (1991) Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 338: 1093-1096.
8. Thornton V, Lennon D, Rasanathan K, O'Hallahan J, Oster P, et al. (2006) Safety and immunogenicity of New Zealand strain meningococcal serogroup B OMV vaccine in healthy adults: beginning of epidemic control. Vaccine 24: 1395-1400.
9. Holst J, Martin D, Arnold R, Huergo CC, Oster P, et al. (2009) Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis. Vaccine 27Suppl 2: B3-12.
10. Claassen I, Meylis J, van der Ley P, Peeters C, Brons H, et al. (1996) Production, characterization and control of a Neisseria meningitidis hexavalent class 1 outer membrane protein containing vesicle vaccine. Vaccine 14: 1001-1008.
11. van de Waterbeemd B, Streefland M, van der Ley P, Zomer B, van Dijken H, et al. (2010) Improved OMV vaccine against Neisseria meningitidis using genetically engineered strains and a detergent-free purification process. Vaccine 28: 4810-4816.
12. Ferrari G, Garaguso I, Adu-Bobie J, Doro F, Taddei AR, et al. (2006) Outer membrane vesicles from group B Neisseria meningitidis delta gna33 mutant: proteomic and immunological comparison with detergent-derived outer membrane vesicles. Proteomics 6: 1856-1866.
13. van der Ley P, Steeghs L, Hamstra HJ, ten Hove J, Zomer B, et al. (2001) Modification of lipid A biosynthesis in Neisseria meningitidis lpxL mutants: influence on lipopolysaccharide structure, toxicity, and adjuvant activity. Infect Immun 69: 5981-5990.
14. Koeberling O, Seubert A, Granoff DM, (2008) Bactericidal antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed factor H-binding protein and genetically attenuated endotoxin. J Infect Dis 198: 262-270.
15. Keiser PB, Biggs-Cicatelli S, Moran EE, Schmiel DH, Pinto VB, et al. (2010) A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression. Vaccine.
16. Weynants V, Denoel P, Devos N, Janssens D, Feron C, et al. (2009) Genetically modified L3,7 and L2 lipooligosaccharides from Neisseria meningitidis serogroup B confer a broad cross-bactericidal response. Infect Immun 77: 2084-2093.
17. Zollinger WD, Donets MA, Schmiel DH, Pinto VB, Labrie J, et al. (2010) Design and evaluation in mice of a broadly protective meningococcal group B native outer membrane vesicle vaccine. Vaccine.
18. Koeberling O, Giuntini S, Seubert A, Granoff DM (2008) Meningococcal OMV Vaccines from Mutant Strains Engineered to Express Factor H Binding Proteins from Antigenic Variant Groups 1 and 2. Clin Vaccine Immunol.
19. van der Ley P, van den Dobbelsteen G, (2011) Next-generation outer membrane vesicle vaccines against Neisseria meningitidis based on nontoxic LPS mutants. Hum Vaccin 7: 886-890.
20. Zollinger WD, Poolman JT, Maiden MC, (2011) Meningococcal serogroup B vaccines: will they live up to expectations? Expert Rev Vaccines 10: 559-561.
21. Post DM, Zhang D, Eastvold JS, Teghanemt A, Gibson BW, et al. (2005) Biochemical and functional characterization of membrane blebs purified from Neisseria meningitidis serogroup B. J Biol Chem. 280: 38383-38394.
22. Hoekstra D, van der Laan JW, de Leij L, Witholt B, (1976) Release of outer membrane fragments from normally growing Escherichia coli. Biochim Biophys Acta 455: 889-899.
23. van de Waterbeemd B, Streefland M, van Keulen L, van den IJssel J, de Haan A, et al. (2012) Identification and optimization of critical process parameters for the production of NOMV vaccine against Neisseria meningitidis. Vaccine 30: 3683-3690.
24. Prachayasittikul V, Isarankura-Na-Ayudhya C, Tantimongcolwat T, Nantasenamat C, Galla HJ, (2007) EDTA-induced membrane fluidization and destabilization: biophysical studies on artificial lipid membranes. Acta Biochim Biophys Sin (Shanghai) 39: 901-913.
25. Haque H, Russell AD, (1974) Effect of chelating agents on the susceptibility of some strains of gram-negative bacteria to some antibacterial agents. Antimicrob Agents Chemother 6: 200-206.
26. Haque H, Russell AD, (1974) Effect of ethylenediaminetetraacetic acid and related chelating agents on whole cells of gram-negative bacteria. Antimicrob Agents Chemother 5: 447-452.
27. Zollinger WD, Kasper DL, Veltri BJ, Artenstein MS, (1972) Isolation and characterization of a native cell wall complex from Neisseria meningitidis. Infect Immun 6: 835-851.
28. Work E, Knox KW, Vesk M, (1966) The chemistry and electron microscopy of an extracellular lipopolysaccharide from Escherichia coli. Ann N Y Acad Sci 133: 438-449.
29. Chatterjee SN, Das J, (1967) Electron microscopic observations on the excretion of cell-wall material by Vibrio cholerae. J Gen Microbiol 49: 1-11.
30. Henry T, Pommier S, Journet L, Bernadac A, Gorvel JP, et al. (2004) Improved methods for producing outer membrane vesicles in Gram-negative bacteria. Res Microbiol 155: 437-446.
31. Katsui N, Tsuchido T, Hiramatsu R, Fujikawa S, Takano M, et al. (1982) Heat-induced blebbing and vesiculation of the outer membrane of Escherichia coli. J Bacteriol 151: 1523-1531.
32. McBroom AJ, Kuehn MJ, (2007) Release of outer membrane vesicles by Gram-negative bacteria is a novel envelope stress response. Mol Microbiol 63: 545-558.
33. Bishop DG, Work E, (1965) An extracellular glycolipid produced by Escherichia coli grown under lysine-limiting conditions. Biochem J 96: 567-576.
34. Knox KW, Vesk M, Work E, (1966) Relation between excreted lipopolysaccharide complexes and surface structures of a lysine-limited culture of Escherichia coli. J Bacteriol 92: 1206-1217.
35. Guckenberger M, Kurz S, Aepinus C, Theiss S, Haller S, et al. (2002) Analysis of the heat shock response of Neisseria meningitidis with cDNA- and oligonucleotide-based DNA microarrays. J Bacteriol 184: 2546-2551.
36. Grifantini R, Frigimelica E, Delany I, Bartolini E, Giovinazzi S, et al. (2004) Characterization of a novel Neisseria meningitidis Fur and iron-regulated operon required for protection from oxidative stress: utility of DNA microarray in the assignment of the biological role of hypothetical genes. Mol Microbiol 54: 962-979.
37. Grifantini R, Sebastian S, Frigimelica E, Draghi M, Bartolini E, et al. (2003) Identification of iron-activated and-repressed Fur-dependent genes by transcriptome analysis of Neisseria meningitidis group B. Proc Natl Acad Sci U S A. 100: 9542-9547.
38. Grifantini R, Bartolini E, Muzzi A, Draghi M, Frigimelica E, et al. (2002) Previously unrecognized vaccine candidates against group B meningococcus identified by DNA microarrays. Nat Biotechnol 20: 914-921.
39. Dietrich G, Kurz S, Hubner C, Aepinus C, Theiss S, et al. (2003) Transcriptome analysis of Neisseria meningitidis during infection. J Bacteriol 185: 155-164.
40. Bartolini E, Frigimelica E, Giovinazzi S, Galli G, Shaik Y, et al. (2006) Role of FNR and FNR-regulated, sugar fermentation genes in Neisseria meningitidis infection. Mol Microbiol 60: 963-972.
41. Tettelin H, Saunders NJ, Heidelberg J, Jeffries AC, Nelson KE, et al. (2000) Complete genome sequence of Neisseria meningitidis serogroup B strain MC58. Science 287: 1809-1815.
42. Holbein BE, (1981) Growth and surface binding of proteins by Neisseria meningitidis in normal human serum. Current Microbiology 6: 213-216.
43. Catlin BW, (1973) Nutritional profiles of Neisseria gonorrhoeae, Neisseria meningitidis, and Neisseria lactamica in chemically defined media and the use of growth requirements for gonococcal typing. J Infect Dis 128: 178-194.
44. Port JL, DeVoe IW, Archibald FS, (1984) Sulphur acquisition by Neisseria meningitidis. Can J Microbiol 30: 1453-1457.
45. Baart GJ, Zomer B, de Haan A, van der Pol LA, Beuvery EC, et al. (2007) Modeling Neisseria meningitidis metabolism: from genome to metabolic fluxes. Genome Biol 8: R136.
46. Grizot S, Buchanan SK, (2004) Structure of the OmpA-like domain of RmpM from Neisseria meningitidis. Mol Microbiol 51: 1027-1037.
47. Klugman KP, Gotschlich EC, Blake MS, (1989) Sequence of the structural gene (rmpM) for the class 4 outer membrane protein of Neisseria meningitidis, homology of the protein to gonococcal protein III and Escherichia coli OmpA, and construction of meningococcal strains that lack class 4 protein. Infect Immun 57: 2066-2071.
48. Jang S, Imlay JA, (2007) Micromolar intracellular hydrogen peroxide disrupts metabolism by damaging iron-sulfur enzymes. J Biol Chem 282: 929-937.
49. Rouault TA, Tong WH, (2005) Iron-sulphur cluster biogenesis and mitochondrial iron homeostasis. Nat Rev Mol Cell Biol 6: 345-351.
50. Bitoun JP, Wu G, Ding H, (2008) Escherichia coli FtnA acts as an iron buffer for re-assembly of iron-sulfur clusters in response to hydrogen peroxide stress. Biometals 21: 693-703.
51. Johnson DC, Dean DR, Smith AD, Johnson MK, (2005) Structure, function, and formation of biological iron-sulfur clusters. Annu Rev Biochem 74: 247-281.
52. Moslen MT, (1994) Reactive oxygen species in normal physiology, cell injury and phagocytosis. Adv Exp Med Biol 366: 17-27.
53. Ng VH, Cox JS, Sousa AO, MacMicking JD, McKinney JD, (2004) Role of KatG catalase-peroxidase in mycobacterial pathogenesis: countering the phagocyte oxidative burst. Mol Microbiol 52: 1291-1302.
54. Zollinger WD (2003) Vaccine against gram negative bacteria- US patent: US6,558,677 B2.
55. Fredriksen JH, Rosenqvist E, Wedege E, Bryn K, Bjune G, et al. (1991) Production, characterization and control of MenB-vaccine "Folkehelsa": an outer membrane vesicle vaccine against group B meningococcal disease. NIPH Ann 14: 67-79; discussion 79-80.
56. Berlanda Scorza F, Colucci AM, Maggiore L, Sanzone S, Rossi O, et al. (2012) High yield production process for Shigella outer membrane particles. PLoS One 7: e35616.
57. Holten E, (1979) Serotypes of Neisseria meningitidis isolated from patients in Norway during the first six months of 1978. J Clin Microbiol 9: 186-188.
58. van der Ley P, van der Biezen J, Poolman JT, (1995) Construction of Neisseria meningitidis strains carrying multiple chromosomal copies of the porA gene for use in the production of a multivalent outer membrane vesicle vaccine. Vaccine 13: 401-407.
59. Baart GJ, de Jong G, Philippi M, van't Riet K, van der Pol LA, et al. (2007) Scale-up for bulk production of vaccine against meningococcal disease. Vaccine 25: 6399-6408.
60. Baart GJ, Langenhof M, van de Waterbeemd B, Hamstra HJ, Zomer B, et al. (2010) Expression of phosphofructokinase in Neisseria meningitidis. Microbiology 156: 530-542.
61. van de Waterbeemd B, Streefland M, Pennings J, van der Pol L, Beuvery C, et al. (2009) Gene-expression-based quality scores indicate optimal harvest point in Bordetella pertussis cultivation for vaccine production. Biotechnol Bioeng 103: 900-908.
62. Schroeder A, Mueller O, Stocker S, Salowsky R, Leiber M, et al. (2006) The RIN: an RNA integrity number for assigning integrity values to RNA measurements. BMC Mol Biol 7: 3.
63. Baart GJ, Willemsen M, Khatami E, de Haan A, Zomer B, et al. (2008) Modeling Neisseria meningitidis B metabolism at different specific growth rates. Biotechnol Bioeng 101: 1022-1035.